Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29246 | 0.75 | — | — | |
| SCHEMBL976714 | 0.71 | TSHR (0.31) | TSHR | |
| SCHEMBL4121654 | 0.67 | — | — | |
| SCHEMBL15466839 | 0.65 | CA1 (0.37) | — | |
| SCHEMBL8492495 | 0.65 | — | — | |
| SCHEMBL917202 | 0.64 | MAOA (0.34) | — | |
| SCHEMBL15154 | 0.62 | TSHR (0.31) | TSHR | |
| SCHEMBL1848730 | 0.60 | — | — | |
| SCHEMBL876180 | 0.60 | TSHR (0.33) | TSHR | |
| SCHEMBL11105969 | 0.59 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8029919-B2 | Phenothiazines, S-oxides, and S,S-dioxides as well as phenoxazines as emitters for OLEDs | BASF AKTIENGESELLSCHAFT (DE) | 2011-10-04 | — | — | US | claimed |
| EP-3008757-B1 | OPTICAL DETECTOR AND METHOD FOR MANUFACTURING THE SAME | BASF SE (DE) | 2024-05-15 | — | — | EP | disclosed |
| US-11605790-B2 | Monosubstituted diazabenzimidazole carbene metal complexes for use in organic light emitting diodes | UDC IRELAND LIMITED (IE) | 2023-03-14 | — | — | US | disclosed |
| EP-3126371-B1 | METAL COMPLEXES, COMPRISING CARBENE LIGANDS HAVING AN O-SUBSTITUTED NON-CYCLOMETALATED ARYL GROUP AND THEIR USE IN ORGANIC LIGHT EMITTING DIODES | UDC IRELAND LTD (IE) | 2021-11-10 | — | — | EP | disclosed |
| US-11125880-B2 | Optical detector | BASF SE (DE) | 2021-09-21 | — | — | US | disclosed |
| US-11041718-B2 | Detector for determining a position of at least one object | BASF SE (DE) | 2021-06-22 | — | — | US | disclosed |
| US-11031559-B2 | Phenoxasiline based compounds for electronic application | UDC IRELAND LIMITED (IE) | 2021-06-08 | — | — | US | disclosed |
| EP-2936052-B1 | DETECTOR FOR OPTICALLY DETECTING AT LEAST ONE OBJECT | BASF SE (DE) | 2021-04-28 | — | — | EP | disclosed |
| EP-2165377-B1 | ORGANIC LIGHT-EMITTING DIODES CONTAINING CARBENE TRANSITION METAL COMPLEX EMITTERS AND AT LEAST ONE COMPOUND SELECTED FROM DISILYLCARBAZOLES, DISILYLDIBENZOFURANS, DISILYLDIBENZOTHIOPHENES, DISILYLDIBENZOPHOSPHOLES, DISILYLDIBENZOTHIOPHENE S-OXIDES AND DISILYLDIBENZOTHIOPHENE S,S-DIOXIDES | UDC IRELAND LTD (IE) | 2021-04-28 | — | — | EP | disclosed |
| EP-3036558-B1 | DETECTOR FOR DETERMINING A POSITION OF AT LEAST ONE OBJECT | BASF SE (DE) | 2020-12-16 | — | — | EP | disclosed |
| WO-2006074957-A1 | SUBSTITUTED AMINOMETHYLENE SULPHONAMIDES, PRODUCTION AND USE THEREOF AS MEDICAMENTS | SANOFI-AVENTIS (DE) | 2006-07-20 | — | — | WO | disclosed |
| WO-2006056465-A1 | PHENOTHIAZINES, -S-OXIDES, AND S,S-DIOXIDES AS WELL AS PHENOXAZINES AS EMITTERS FOR OLEDS | BASF AKTIENGESELLSCHAFT (DE) | 2006-06-01 | — | — | WO | disclosed |
| WO-2006018279-A2 | ARYL-SUBSTITUTED POLYCYCLIC AMINES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006018280-A2 | ARYL-SUBSTITUTED POLYCYCLIC AMINES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-02-23 | — | — | WO | disclosed |
| EP-1604988-A1 | Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals | Sanofi-Aventis Deutschland GmbH (DE) | 2005-12-14 | — | — | EP | disclosed |
| EP-1598348-A1 | Novel pyridazinone derivatives as inhibitors of CDK2 | Aventis Pharma Deutschland GmbH (DE) | 2005-11-23 | — | — | EP | disclosed |
| US-20050176795-A1 | Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH | 2005-08-11 | — | — | US | disclosed |
| US-20050176710-A1 | Aryl-substituted heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-08-11 | — | — | US | disclosed |
| WO-2005070898-A1 | SUBSTITUTED N-CYCLOHEXYL IMIDAZOLINONES HAVING AN MCH-MODULATORY EFFECT | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005070925-A1 | ARYL SUBSTITUTED HETEROCYCLES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176710-A1 | Aryl-substituted heterocycles, process for their preparation and their use as medicaments | CYP11B1, CYP11B2, GPR119 | TSHR 1013/4885 |
| US-11605790-B2 | Monosubstituted diazabenzimidazole carbene metal complexes for use in organic light emitting diodes | DDT, OCIAD1, OCIAD2 | TSHR 3463/4885 |
| US-20050176795-A1 | Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments | CYP11B1, CYP11B2, GPR119 | TSHR 3067/4885 |
| US-11031559-B2 | Phenoxasiline based compounds for electronic application | PPOX, FZD7, OGFOD1 | TSHR 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.